Bio-Path Holdings Company Profile (NASDAQ:BPTH)

Analyst Ratings

Consensus Ratings for Bio-Path Holdings (NASDAQ:BPTH) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (194.12% upside)

Analysts' Ratings History for Bio-Path Holdings (NASDAQ:BPTH)
Show:
DateFirmActionRatingPrice TargetActions
7/11/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Bio-Path Holdings (NASDAQ:BPTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/11/2016Q1($0.01)($0.02)$2.33 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q4($0.01)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015$0.01($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/18/2014($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/18/2014Q214($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/2/2014$0.01$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Path Holdings (NASDAQ:BPTH)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Bio-Path Holdings (NASDAQ:BPTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bio-Path Holdings (NASDAQ:BPTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bio-Path Holdings (NASDAQ:BPTH)
DateHeadline
07/23/16 02:53 PMStock Displaying Signs of a Downtrend: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Press Telegraph
07/19/16 02:57 PMBio Path Holdings DE (NASDAQ:BPTH) Shorted Shares Increased By 216.62% - Consumer Eagle
07/19/16 09:10 AMTop News: Bio-Path Holdings, Inc. (NASDAQ:BPTH), Great Basin Scientific, Inc. (NASDAQ:GBSN), Acasti Pharma Inc ... - KC Register
07/19/16 09:10 AMBio-Path Holdings (BPTH) Updated Price Targets - FTSE News
07/17/16 02:47 PMShares Moving Down on the Week: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Engelwood Daily
07/16/16 07:28 AMShares Experiencing a Downtrend: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - TGP
07/13/16 11:02 AMShare Volatility Watch for: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Engelwood Daily
07/13/16 11:02 AMBio-path Holdings Inc (NASDAQ:BPTH) Sentiment Change Report - Consumer Eagle
07/06/16 07:00 AMBio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference - [GlobeNewswire] - HOUSTON, July 06, 2016-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
07/05/16 02:57 PMHouston biotech firm collaborates with university on brain cancer therapy
07/02/16 02:57 PMCompany Stock Lower on the Week Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Engelwood Daily
07/01/16 05:05 AMBIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/30/16 05:10 AMBIO-PATH HOLDINGS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme -
06/29/16 07:59 PMBio Path : Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer
06/29/16 02:53 PMStock Tracking Lower in Session: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Telanagana Press
06/29/16 02:53 PMBio-Path Holdings (BPTH) Enters $10M Stock, Warrants Registered Direct Offering - StreetInsider.com
06/29/16 11:39 AMBRIEF-Bio Path Holdings announces $10 million registered direct offering - * Bio-Path Holdings, Inc. announces $10 million registered direct offering
06/29/16 10:59 AMBio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering - [GlobeNewswire] - HOUSTON, June 29, 2016-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
06/28/16 07:24 AMBio-Path Holdings (BPTH) Enters Brain Cancer Treatment Collaboration with TJU - StreetInsider.com
06/28/16 07:02 AM8:02 am Bio-Path enters into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize -
06/28/16 07:00 AMBio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer - [GlobeNewswire] - HOUSTON, June 28, 2016-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
06/27/16 02:36 PMStock Volatility in Review: Bio-Path Holdings, Inc. (NASDAQ:BPTH) - Engelwood Daily
06/27/16 02:36 PMBio-Path Holdings Inc. (NASDAQ: BPTH) Joins The Russell 3000 Index - Scibility Media
06/27/16 07:35 AMNew Broker Ratings For Bio-Path Holdings (BPTH) - FTSE News
06/27/16 07:35 AMHC Stocks to Path: Athersys, Inc. (NASDAQ:ATHX), Bio-Path Holdings Inc (NASDAQ:BPTH) - share market updates (press release)
06/24/16 05:34 AMBio-Path Holdings Inc. (BPTH) is Trading Lower on Unusual Volume for June 22 - Equities.com
06/23/16 10:58 AMBio-Path Holdings Inc. (BPTH) Jumps 10.1% on June 21 - Equities.com
06/23/16 10:58 AMBio-Path Holdings Inc. (BPTH) is Trading Higher on Unusual Volume for June 21 - Equities.com
06/20/16 03:01 PMBio-Path Holdings to Join Russell 3000® and Global Indexes - [GlobeNewswire] - HOUSTON, June 20, 2016-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
06/19/16 02:47 PMThis Weeks Broker Views For Bio-Path Holdings (BPTH) - Fiscal Standard
06/16/16 07:19 AMBio-Path Holdings Inc. (BPTH) is Trading Lower on Unusual Volume for June 14 - Equities.com
06/16/16 07:19 AMBio-Path Holdings Inc. (BPTH) Drops 8.07% on June 14 - Equities.com
06/15/16 07:45 AMBio-Path Holdings Inc. (BPTH) Drops 8.23% on June 13 - Equities.com
06/14/16 08:08 AMAlcoa Inc. (NYSE:AA) decreased -1.79%: ConocoPhillips (NYSE:COP), Bio-Path Holdings, Inc. (NASDAQ:BPTH ... - KC Register
06/08/16 09:21 PMBio-Path Holdings Inc. (BPTH) Drops 5.06% on June 07 - Equities.com
06/06/16 01:27 PMBio-Path Holdings, Inc. :BPTH-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/06/16 09:27 AMBio-Path Holdings (BPTH) Announces Presentation of BP1001 Phase 2 Data in AML at ASCO - StreetInsider.com
06/06/16 08:00 AMBio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016 - [GlobeNewswire] - HOUSTON, June 06, 2016-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
06/03/16 03:02 PMBroker Watchlist: Bio-Path Holdings (BPTH) - Share Trading News
06/01/16 11:29 AMBuy, Sell Or Hold Rating For Bio-Path Holdings (BPTH)? - Share Trading News - Buy, Sell Or Hold Rating For Bio-Path Holdings (BPTH)?Share Trading News04/18/2016 – Rodman & Renshaw began new coverage on Bio-Path Holdings giving the company a “buy” rating. They now have a USD 5 price target on the stock. 10/14/2015 – Bio-Path Holdings had its “buy” rating reiterated by analysts at Maxim Group.
05/27/16 10:40 AMBio-Path Holdings, Inc. (NASDAQ:BPTH) Closes At $2.720 - RealistInvestor.com - Bio-Path Holdings, Inc. (NASDAQ:BPTH) Closes At $2.720RealistInvestor.comThe technical analysis of Bio-Path Holdings, Inc. (NASDAQ:BPTH) stock highlights the stock is $0.084 points away +3.162% from its 50-day MA of $2.671. It is $0.856 or +45.044% away $1.899, the 200-day Moving Average (MA) of stock. Yesterday, the stock ...
05/26/16 05:25 AMHold Calls Count For Bio-Path Holdings, Inc. (NASDAQ:BPTH) At 0 - Investor Newswire - Hold Calls Count For Bio-Path Holdings, Inc. (NASDAQ:BPTH) At 0Investor NewswireBuy calls count on Bio-Path Holdings, Inc. (NASDAQ:BPTH)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. Bio-Path Holdings, Inc. (NASDAQ:BPTH) has a total of 2 Strong Buy recommendations and 0 Strong Sell advises as ...and more »
05/26/16 05:25 AMBIO-PATH HOLDINGS INC (BPTH) Jumps 5.99% on May 23 - Equities.com - BIO-PATH HOLDINGS INC (BPTH) Jumps 5.99% on May 23Equities.comBIO-PATH HOLDINGS INC (BPTH) was among the biggest gainers on the Russell 2000 for Monday May 23 as the stock popped 5.99% to $2.83, representing a gain of $0.16 per share. Some 259,985 shares traded hands on 993 trades, compared with an ...
05/21/16 02:06 PMRevenue Update on Bio-Path Holdings Inc(NASDAQ:BPTH) - Trade Calls - Revenue Update on Bio-Path Holdings Inc(NASDAQ:BPTH)Trade CallsBio-Path Holdings Inc(NASDAQ:BPTH) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 11, 2016. Earnings per share were $-0.02. In a different note, Rodman & Renshaw said it Initiates Coverage ...Bio-Path Holdings, Inc. (NASDAQ:BPTH) Reports Basic Consolidated EPS At $-0.0609Markets Dailyall 2 news articles »
05/20/16 01:51 PMBIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure -
05/19/16 06:30 AMBio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting - [GlobeNewswire] - HOUSTON, May 19, 2016-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
05/12/16 09:13 AMBio-Path Holdings Inc (BPTH) Releases Earnings Results, Misses Expectations By $0.01 EPS - Washington News Wire - Washington News WireBio-Path Holdings Inc (BPTH) Releases Earnings Results, Misses Expectations By $0.01 EPSWashington News WireBio-Path Holdings logo Bio-Path Holdings Inc (NASDAQ:BPTH) issued its quarterly earnings data on Wednesday. The company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.01, Market Beat ...
05/11/16 06:39 AMBio-Path reports 1Q loss -
05/11/16 06:30 AMBio-Path Holdings Reports First Quarter 2016 Financial Results - [GlobeNewswire] - HOUSTON, May 11, 2016-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
05/11/16 06:07 AMQ1 2016 Bio Path Holdings Inc Earnings Release - Time Not Supplied -

Social

About Bio-Path Holdings

Bio-Path Holdings logoBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BPTH
  • CUSIP:
Key Metrics:
  • Previous Close: $1.70
  • 50 Day Moving Average: $1.90
  • 200 Day Moving Average: $2.07
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $152.60M
  • Beta: 1.42
  • Current Year EPS Consensus Estimate: $-0.08 EPS
  • Next Year EPS Consensus Estimate: $-0.09 EPS
Additional Links:
Bio-Path Holdings (NASDAQ:BPTH) Chart for Saturday, July, 30, 2016